Can Amgen (AMGN) Stock Reach $500?

Key Takeaways

• The price target in question is $500, roughly 32% above Amgen's recent trading range near $377–$380 and about 12% above its 52-week high of $447.03.
• Strongest bullish factors: a broad, diversified drug portfolio, accelerating growth in Repatha, Evenity, Tepezza, and Uplizna, and a recent positive oncology readout.
• Biggest obstacle: Novartis's failed Lp(a) trial has cast doubt on Amgen's own olpasiran program, whose key data does not arrive until 2028.
• Key technical levels: $447–$450 marks the all-time-high resistance zone, while the recent lows near $377–$380 and the psychological $350 area serve as support.
• Investor takeaway: $500 is plausible over a multi-year horizon but is not supported by current consensus forecasts, which cluster well below that level.

Why Investors Are Watching the $500 Level

Amgen Inc. (AMGN) is one of the world's largest biotechnology companies, with a market capitalization of roughly $204 billion and a portfolio spanning cardiovascular care, oncology, bone health, inflammation, and biosimilars. The stock has been a standout performer, rallying more than 60% over the past year and reaching an all-time high of $447.03 in early September 2026. That surge has naturally pushed investors to ask whether the next major milestone—the psychologically significant $500 mark—is within reach.

Current Market Position

After peaking near $447, Amgen shares reversed sharply. On September 8, 2026, the stock fell about 10% in its worst single session since October 2000, and it has since drifted into the $377–$380 range. Despite the pullback, the shares remain well above their 52-week low of $269.77. Amgen trades at a trailing price-to-earnings (P/E) ratio of roughly 23 and offers a dividend yield of about 2.6%, supported by an annualized payout near $10 per share.

What Could Drive the Next Leg Higher

Amgen's fundamentals were strengthening before the recent selloff. The company's second-quarter 2026 results beat expectations, with adjusted earnings per share of $6.29 and revenue of approximately $10.1 billion, prompting management to raise full-year guidance. Growth is increasingly concentrated in newer franchises: Repatha, a cholesterol-lowering PCSK9 inhibitor, grew revenue 37% year over year, while Evenity, Tepezza, and Uplizna also outpaced forecasts. The company additionally reported a positive Phase 3 readout for IMDELLTRA in extensive-stage small cell lung cancer, underscoring a pipeline that is not reliant on any single program.

Achieving $500 would likely require continued double-digit growth from these newer drugs, meaningful progress in the obesity candidate MariTide, and a recovery in sentiment toward the cardiovascular pipeline.

What Could Prevent the Move

The most significant near-term obstacle is a read-through from a rival. On September 4, 2026, Novartis (NVS) announced that its Lp(a)-lowering therapy pelacarsen failed a Phase 3 cardiovascular outcomes trial. Although Amgen's own Lp(a) candidate, olpasiran, uses a different molecular approach and showed deeper Lp(a) reduction in earlier studies, the failure challenged the underlying hypothesis that lowering Lp(a) prevents cardiovascular events. With Amgen's own outcomes data not expected until 2028, the uncertainty is likely to linger.

Beyond that single event, Amgen faces patent expirations across legacy franchises such as Prolia, Xgeva, Enbrel, and Otezla, with biosimilar competition intensifying. Analysts also caution that further re-rating depends heavily on obesity-trial readouts in an increasingly crowded space.

Analyst Opinions and Price Targets

Wall Street's view is measured. The consensus analyst price target sits near $381, roughly in line with the current price, with ratings clustered around a "Hold." Individual targets range widely, from $230 on the bearish end to $450–$452 at the top (including TD Cowen, Scotiabank, and Oppenheimer). Notably, even the most bullish published targets fall short of $500, meaning the stock would need to exceed every current analyst estimate to reach that milestone. Several firms, including HSBC and BMO, have recently trimmed ratings or targets following the Lp(a) setback.

Technical Levels That Matter

From a technical-analysis perspective, the $447–$450 zone now represents a major resistance level, as it marks both the 52-week high and a round-number area. Any sustainable move toward $500 would first require reclaiming and holding above that level. On the downside, the $377–$380 area has provided support following the selloff, with $350 as the next psychological cushion. The long-term trend structure remains upward, given the stock's dramatic recovery from its 52-week low, but the sharp September reversal suggests supply has re-emerged near the highs.

AI Daily Buy/Sell Signals

For traders monitoring whether Amgen can rebuild momentum toward $500, Tickeron's AI Daily Buy/Sell Signals offer a data-driven way to track shifting conditions. The platform uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, monitor existing positions, and identify changing market trends more efficiently. Exploring the AI Daily Buy/Sell Signals may help investors stay ahead of evolving technical setups in Amgen and across the broader market.

Final Assessment

Can Amgen realistically reach $500? The path exists, but it is a multi-year proposition rather than a near-term probability. The company's diversified portfolio, accelerating growth in key brands, and healthy cash generation provide a credible foundation, and $500 sits only modestly above the stock's recent all-time high. However, the Lp(a) overhang, looming patent cliffs, and a consensus analyst target well below $500 all argue for caution. Reaching $500 would likely require successful obesity and cardiovascular pipeline readouts, continued double-digit growth in newer products, and a decisive break above the $447–$450 resistance zone. Investors should monitor upcoming clinical catalysts, earnings momentum, and the stock's ability to hold the $377–$380 support area before drawing any conclusions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations